We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal Impairment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00159614
Recruitment Status : Completed
First Posted : September 12, 2005
Last Update Posted : January 29, 2008
Merck Sharp & Dohme Corp.
Information provided by:
NovaCardia, Inc.

Brief Summary:
The purpose of this study is to characterize the safety and tolerability of KW-3902IV and measure its effect on renal function.

Condition or disease Intervention/treatment Phase
Heart Failure, Congestive Renal Insufficiency Drug: KW-3902IV Phase 2

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With Congestive Heart Failure (CHF) and Renal Impairment
Study Start Date : September 2005

Resource links provided by the National Library of Medicine

Drug Information available for: Furosemide
U.S. FDA Resources

Primary Outcome Measures :
  1. Comparison of KW-3902IV alone or with loop diuretic on renal function.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Stable congestive heart failure
  • Impaired renal function
  • Taking oral loop diuretic

Exclusion Criteria:

  • Acutely decompensated (unstable) and end stage heart failure
  • Diuretics other than loop diuretics
  • Pregnant or nursing
  • Inability to follow instructions
  • Participation in another clinical trial within past 30 days

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00159614

United States, California
San Diego, California, United States
United States, Maryland
Baltimore, Maryland, United States
United States, Massachusetts
Ayer, Massachusetts, United States
Boston, Massachusetts, United States
United States, Michigan
Kalamazoo, Michigan, United States
United States, Tennessee
Tullahoma, Tennessee, United States
Sponsors and Collaborators
NovaCardia, Inc.
Merck Sharp & Dohme Corp.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00159614     History of Changes
Other Study ID Numbers: CKI-203
First Posted: September 12, 2005    Key Record Dates
Last Update Posted: January 29, 2008
Last Verified: January 2008

Keywords provided by NovaCardia, Inc.:
renal insufficiency
heart failure, congestive

Additional relevant MeSH terms:
Heart Failure
Renal Insufficiency
Heart Diseases
Cardiovascular Diseases
Kidney Diseases
Urologic Diseases
Natriuretic Agents
Physiological Effects of Drugs
Sodium Potassium Chloride Symporter Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action